JPRN-jRCT2080223511: a phase III, multicenter, randomized, double-blind, placebo controlled, parallel group study of KRP-116D in Japanese patients with interstitial cystitis (2017)

Other · Kyorin Pharmaceutical Co., Ltd (sponsor); Japan Registry of Clinical Trials (jRCT) · April 20, 2017

Kyorin Pharmaceutical Co. et al., 2017-04-20: The Japanese phase III registration for the trial that became the Zymso approval: 90 patients planned, multicentre randomised double-blind placebo-controlled, first enrolment 25 May 2017, completed, with results available and linked to the 2021 publication.

Results available: Yes

Results field of the registry record

Kyorin Pharmaceutical Co. et al., 2017-04-20: The Japanese phase III registration for the trial that became the Zymso approval: 90 patients planned, multicentre randomised double-blind placebo-controlled, first enrolment 25 May 2017, completed, with results available and linked to the 2021 publication. C9/C5 Japanese registry record. Record fields: phase 3; target sample size 90; sponsor Kyorin Pharmaceutical; intervention KRP-116D (INN dimethyl sulfoxide), 50 mL intravesical once every two weeks against placebo; primary outcome O'Leary and Sant's IC symptom index; secondary ID JapicCTI-173566; date of completion 18/01/2021 (as printed); results URL https://pubmed.ncbi.nlm.nih.gov/33580603/. Country: Japan. Comparator: placebo. Results posted.